The global cancer vaccines market size is estimated to be growing at a CAGR of 17.28% during the forecast period. As a result, the market size is projected to value USD 14.02 billion by 2028 from USD 6.32 billion in 2023.
Vaccines were mostly used to prevent contagious diseases; they work by improving the immune response against pathogens. Similarly, cancer vaccines work by activating the immune system to attack cancer cells. Researchers developed therapeutic cancer vaccines to alleviate patients suffering from cancer. With the new technological advances, cancer vaccines have been developed as a new therapeutic way for cancer prevention and eradication. Broad ranges of therapeutics are currently available to combat cancer effectively, but they suffer from many glitches like low effectiveness and high specificity.
MARKET DRIVERS:
The growing cancer patient population worldwide is propelling the cancer vaccines market growth primarily.
The influx of novel cancer vaccines into the market contributes to developing the global cancer vaccines market. The increase in demand for preventive vaccines among people due to increased awareness of infectious diseases catalyzes the growth of the cancer vaccines market. Also, governments and private organizations' increased investments to produce cancer vaccines and the development of alternative therapies due to a consistently rising account of cancer contribute to the growth of the global cancer vaccines market.
Steadily increasing demand and adoption rates of therapeutic and preventive vaccines are expected to create lucrative growth opportunities for key market players in the global cancer vaccines market during the outlook period. Emerging economies of developing nations such as China and India are leading to the expansion and technological advancement of healthcare. They will likely offer many growth opportunities for the stakeholders operating in the worldwide cancer vaccines market. Increased focus of medical professionals on research and development of alternative therapies and treatments owing to the continually growing prevalence of cancer at an exponential rate is likely to provide lucrative growth opportunities for the key players functioning in the cancer vaccines market during the projection period.
MARKET RESTRAINTS:
Stringent regulations and time-taking approval procedures of the FDA, restricting or delaying the launch of newly developed vaccines into the market, are a challenge to the key players and stakeholders, eventually limiting the growth of the cancer vaccines market. Side effects associated with the available therapies are challenging the development of the global cancer vaccine market.
Impact of COVID-19 on the global cancer vaccines market:
COVID-19 was declared an international public health emergency by the World Health Organization (WHO) on January 30, 2020. About 210 countries have been affected by COVID-19. It is a large virus family that causes many illnesses, from the common cold to more serious respiratory illnesses. Some businesses, particularly those with insufficient liquidity, can be stressed by temporary disruptions in inputs or output. Furthermore, delayed shipments and production schedules cause financial difficulties for businesses with high debt levels. Due to shutdowns in various COVID-19-affected countries, the COVID-19 pandemic has slowed cancer vaccine production and the import and export of raw materials and finished products. Cancer (also known as malignant tumors or neoplasm) is a condition in which abnormal cells develop and invade other tissues uncontrolled. This could result in cancer tumors spreading uncontrollably across the body. However, the cancer vaccine market is projected to have a significant growth rate in the coming years.
REPORT COVERAGE:
REPORT METRIC |
DETAILS |
Market Size Available |
2022 to 2028 |
Base Year |
2022 |
Forecast Period |
2023 to 2028 |
Segments Covered |
By Cancer Type, Vaccine Type, End Users, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech |
This research report on the global cancer vaccines market has been segmented and sub-segmented based on the cancer type, vaccine type, end-users, and region.
Cancer Vaccines Market - By Cancer Type:
Based on the cancer type, the cervical cancer segment accounted for the largest share of the global cancer vaccines market share in 2022 and is expected to maintain its dominance over the forecast period, owing to an increase in the number of people infected with the human papillomavirus (HPV). Furthermore, the high prevalence of cervical cancer drives market development.
On the other hand, the prostate cancer segment is projected to expand at the fastest rate of 14.10% CAGR during the forecast period owing to increased demand for Provenge (prostate cancer vaccine) and an increase in the number of prostate cancer vaccines in development.
Cancer Vaccines Market - By Vaccine Type:
Based on the vaccine type, the global demand for recombinant cancer vaccines dominated in 2022 and is projected to continue over the forecast period. This is because recombinant technology has been used to authorize several cancer vaccines, including Cervarix.
Cancer Vaccines Market - By End User:
Based on end-users, the cancer treatment centers segment contributes the largest share of revenues to the global cancer vaccines market. They are likely to continue the trend over the estimated period owing to the huge patient pool.
Cancer Vaccines Market - By Region:
Geographically, North America is predicted to account for the largest share of the global cancer vaccines market due to increased cancer deaths. The government's escalating awareness about cancer by the government grows the patient’s treatment. High prevalence of cancer and the region's developed healthcare system, North America is projected to expand. According to the National Cancer Centre, cancers can be avoided using vaccines such as the Human papillomavirus (HPV) vaccine and the Hepatitis B virus vaccine (HBV). This vaccine is now recommended for men who have advanced types of cancer. Also, the FDA approved talimogene laherparepvec (T-VEC, or Imlygic), the first oncolytic virus therapy, in October 2015. This vaccine is used to treat metastatic melanoma that cannot be removed surgically.
The Asia Pacific is expected to show the highest growth due to increased healthcare expenditure in developing countries in this region. Increasing cancer vaccine acceptance, an increase in the number of cancer patients in emerging economies, the growth of the R&D industry, healthcare reforms, and technological advances in cancer vaccines are providing lucrative opportunities for key players operating in the cancer vaccines market in the Asia Pacific. Furthermore, increased investment from the public and private sectors to develop novel cancer vaccines, an increased number of hospitals and diagnostic centers with advanced medical facilities, and a large population base contribute to the market's growth. Besides that, leading manufacturers' increased emphasis on expanding their geographical presence in developing Asia-Pacific countries to capture a high market share is expected to fuel the region's cancer vaccines market growth.
KEY MARKET PLAYERS:
Companies that are playing a leading role in the global cancer vaccines market profiled in the report are Dendreon, GlaxoSmithKline, Merck, Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, OncoThyreon, Oncovir, Oxford BioMedica, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen and Vaxon Biotech.
RECENT MARKET HAPPENINGS:
FAQ's
The global cancer vaccines market was valued at USD 5.39 billion in 2022.
The increasing incidence of cancer, rising demand for personalized medicine, and advancements in genomics and proteomics technologies are some of the key drivers of the cancer vaccines market
Some key players in the cancer vaccines market include Merck & Co., GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, and AstraZeneca.
Some challenges facing the cancer vaccines market include high development costs, regulatory hurdles, and the complexity of the immune system.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com